Hype or hope? A review of challenges in balancing tumor control and treatment toxicity in breast cancer from the perspective of the radiation oncologist
AbstractThe aim of this article is to discuss the challenges and new strategies in managing breast cancer patients, with a specific focus on radiation oncology and the importance of balancing oncologic outcomes with quality of life and post-treatment morbidity. A comprehensive literature review was conducted to identify advances in the management of breast cancer, exploring de-escalation strategies, hypofractionation schemes, predictors and tools for reducing toxicity (radiation-induced lymphocyte apoptosis, deep inspiration breath-hold, adaptive radiotherapy), enhancer treatments (hyperthermia, immunotherapy) and innovati...
Source: Clinical and Translational Oncology - February 16, 2024 Category: Cancer & Oncology Source Type: research

Difficulties on the access to innovative targeted therapies for lung cancer in Spain
ConclusionSLCG considers imperative to improve the access in Spain to innovative treatments for NSCLC to reduce inequity across European countries. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 16, 2024 Category: Cancer & Oncology Source Type: research

MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis
ConclusionMMP11 and MMP17 may affect UCEC prognosis by influencing immune cell infiltration and may be potential UCEC biomarkers. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 16, 2024 Category: Cancer & Oncology Source Type: research

Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients ’ healthcare in Spain
AbstractCancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk of bleeding while anticoagulated. In addition, cancer therapies have been associated to increased VTE risk. Guidelines for VTE treatment in cancer patients recommend low molecular weight heparins (LMWH) or direct oral anticoagulants (DOAC) for the initial treatment, DOAC for VTE short-term treatment, and LMWH or DOAC for VTE long-term treatment. This consensus article arises from a collaboration between different Spanish experts on cancer-associated thrombosis. It aims to reach an agreement on a practical document of recom...
Source: Clinical and Translational Oncology - February 13, 2024 Category: Cancer & Oncology Source Type: research

Acknowledgement to reviewers: 2023
(Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 13, 2024 Category: Cancer & Oncology Source Type: research

Towards stronger tobacco control policies to curb the smoking epidemic in Spain
AbstractSmoking and exposure to secondhand smoke pose a significant risk to the health of populations. Although this evidence is not new, the commitment of countries to implement laws aimed at controlling consumption and eliminating exposure to secondhand smoke is uneven. Thus, in North America or in Europe, locations like California or Ireland, are pioneers in establishing policies aimed at protecting the population against smoking and secondhand smoke. Identifying measures that have worked would help control this important Public Health problem in other countries that are further behind in tobacco control policies. In Sp...
Source: Clinical and Translational Oncology - February 12, 2024 Category: Cancer & Oncology Source Type: research

Criteria and indicators to evaluate quality of care in genitourinary tumour boards
ConclusionsCriteria and indicators were developed to evaluate the quality of GUMTBs, aiming to serve as a guide to improve quality of care and health outcomes in patients with GU cancer. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 11, 2024 Category: Cancer & Oncology Source Type: research

Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management
The objective of this report is to provide guidance on the prophylaxis, monitoring, and management of adverse events (AEs) in patients with breast cancer treated with T-DXd, and to emphasize that proper management of AEs is needed to optimize the effectiveness of T-DXd treatment and reduce the number of discontinuations. The article covers various aspects of T-DXd treatment, including its clinical efficacy, safety profile, and dos ing considerations, and provides practical recommendations for managing AEs, such as nausea/vomiting, interstitial lung disease, and hematologic toxicity. Although there are still many knowledge ...
Source: Clinical and Translational Oncology - February 9, 2024 Category: Cancer & Oncology Source Type: research

Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
ConclusionsThe addition of atezolizumab to EP as a first-line treatment for ES-SCLC was found to improve survival outcomes. This treatment combination may also prolong PFS in patients with BM, regardless of the administration of cranial irradiation. However, among the BM patients in our study, there was no significant difference in OS between the two treatment groups. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 8, 2024 Category: Cancer & Oncology Source Type: research

Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors
ConclusionWe demonstrated that Doxorubicin, Epirubicin, Liposomal Doxorubicin (Anthracycline), and other drugs adversely affected cardiac function in osteosarcoma patients, increasing the risk of cardiac toxicity. Therefore, close monitoring of cardiac function during chemotherapy is crucial, and timely adjustments to the chemotherapy regimen are necessary. In addition, rational control of drug selection and dosage is essential to minimize the occurrence of cardiac toxicity. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 8, 2024 Category: Cancer & Oncology Source Type: research

What ’s new about the tumor microenvironment of urothelial carcinoma?
This article reviews the current state of knowledge of the different cell populations that compose the tumor microenvironment of urothelial carcinoma, its main functions, and distinct interactions with other cellular and non-cellular components, molecular alterations and aberrant signaling pathways already identified. It also focuses on the clinical implications of these findings, and its potential to translate into improved quality of life and overall survival. Determining new targets or defining prognostic signatures for urothelial carcinoma is an ongoing challenge that could be accelerated through a deeper understanding...
Source: Clinical and Translational Oncology - February 8, 2024 Category: Cancer & Oncology Source Type: research

Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology
AbstractIn the context of pancreatic cancer, surgical intervention is typically recommended for localized tumours, whereas chemotherapy is the preferred approach in the advanced and/or metastatic setting. However, pancreatic cancer is closely linked to ageing, with an average diagnosis at 72  years. Paradoxically, despite its increased occurrence among older individuals, this population is often underrepresented in clinical studies, complicating the decision-making process. Age alone should not determine the therapeutic strategy but, given the high comorbidity and mortality of this dis ease, a comprehensive geriatric asse...
Source: Clinical and Translational Oncology - February 8, 2024 Category: Cancer & Oncology Source Type: research

Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
ConclusionsThe addition of atezolizumab to EP as a first-line treatment for ES-SCLC was found to improve survival outcomes. This treatment combination may also prolong PFS in patients with BM, regardless of the administration of cranial irradiation. However, among the BM patients in our study, there was no significant difference in OS between the two treatment groups. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 8, 2024 Category: Cancer & Oncology Source Type: research

Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors
ConclusionWe demonstrated that Doxorubicin, Epirubicin, Liposomal Doxorubicin (Anthracycline), and other drugs adversely affected cardiac function in osteosarcoma patients, increasing the risk of cardiac toxicity. Therefore, close monitoring of cardiac function during chemotherapy is crucial, and timely adjustments to the chemotherapy regimen are necessary. In addition, rational control of drug selection and dosage is essential to minimize the occurrence of cardiac toxicity. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - February 8, 2024 Category: Cancer & Oncology Source Type: research